Last reviewed · How we verify
BIBX 245 CL- fasted — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
BIBX 245 CL- fasted (BIBX 245 CL- fasted) — Boehringer Ingelheim.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| BIBX 245 CL- fasted TARGET | BIBX 245 CL- fasted | Boehringer Ingelheim | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- BIBX 245 CL- fasted CI watch — RSS
- BIBX 245 CL- fasted CI watch — Atom
- BIBX 245 CL- fasted CI watch — JSON
- BIBX 245 CL- fasted alone — RSS
Cite this brief
Drug Landscape (2026). BIBX 245 CL- fasted — Competitive Intelligence Brief. https://druglandscape.com/ci/bibx-245-cl-fasted. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab